Email This Article

Headlines & Perspectives
FDA Extends Bristol Diabetes Drug Deadline
By Samantha Shaddock
04/23/09 - 04:28 PM EDT
Bristol-Myers Squibb and AstraZeneca say the Food and Drug Administration has extended its timeline for review of diabetes drug ONGLYZA.
Recipient's Email Address(es)
(Separate multiple addresses with a comma)
Your Email Address
Send a copy to myself
Your Message (optional)

Privacy Policy

The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.

Dow Jones S&P 500 NASDAQ 10-Year Note
10,390.11 1,103.25 2,189.61 33.73
Oil *
75.74
UP
1.21
DOWN
2.73
DOWN
4.74
DOWN
0.75
10 Yr
3.37%
SPDR Gold
113.11
+0.01%
-0.25%
-0.22%
-2.18%
Data delayed 20 minutes

Brokerage Partners